New Therapy Improves Immune Response

April 15, 2011 — In a novel approach that works around the gene defect in Wiskott-Aldrich syndrome, an inherited immune deficiency disorder, researchers used an alternative cell signaling pathway to significantly improve immune function in a 13-year-old boy with the disease. The study, at The Children’s Hospital of Philadelphia, provides a proof-of-principle that immunotherapy, which harnesses elements of the body’s immune system, may be used to treat this rare but often deadly disorder.

“If this encouraging initial result holds up in further clinical studies, we may have a new treatment option for patients with Wiskott-Aldrich syndrome,” said pediatric immunologist Jordan S. Orange, MD, PhD, who holds the newly established Jeffrey Modell Endowed Chair in Pediatric Immunology Research at Children’s Hospital.

The immunotherapy study appears in the April 2011 issue of The Journal of Clinical Investigation.

About Wiskott-Aldrich syndrome

Wiskott-Aldrich syndrome (WAS) is a complex immunodeficiency disorder characterized by recurrent infections, eczema and thrombocytopenia (a low platelet count). Mutations in the WAS gene disable its ability to produce WAS protein (WASp), which crucially affects immune cells — particularly natural killer (NK) cells, a major component of the innate immune system. Without WASp, immune defenses are compromised, leaving WAS patients at risk for premature death from infection and cancers. This risk exists even for patients mildly affected by WAS.

The only current cure for WAS is stem cell transplantation, a potentially risky procedure presently justified in severe cases. In addition, Orange recently contributed to a small experimental study of gene therapy for WAS led by European researchers, which achieved clinical benefits in two severely affected young boys.

A new approach to treatment: using an alternate pathway

The current study represents a different approach from either stem cell transplantation or gene therapy. Instead of introducing normally functioning immune cells or inserting DNA to correct the defective gene, Orange and colleagues identified and made use of an alternative pathway to restoring immune function.

The researchers used interleukin-2 (IL-2), a cytokine, or cell-signaling protein, a naturally occurring molecule with a key role in the immune system. In a series of cell studies, they revealed mechanisms by which IL-2 signals control actin filaments, cell structures that enable natural killer cells to mount an effective immune response.

“IL-2 enables NK cells to become cytotoxic — to kill foreign cells,” said Orange. “This happens even in the absence of WASp, the protein that is deficient in WAS patients.”

Researchers in Orange’s laboratory found that in cell cultures, IL-2 induced the function of a protein called WAVE2, similar to WASp, but independent of it. The WAVE2 protein acted similarly to WASp, but was accessed through an alternative pathway that enables function in NK cells.

Teen in study benefits from treatment

Most importantly, IL-2 achieved clinical laboratory benefits in a teenaged patient in this study. The patient, a 13-year-old boy with mild WAS, had suffered recurrent respiratory tract infections and several of his uncles had died prematurely from blood-cell cancers.

The researchers injected the patient with pharmaceutically produced IL-2 in three treatment courses over 27 weeks. At the end of treatment, the patient’s NK cells had cytotoxicity nearly identical to that of a healthy control subject. He tolerated the IL-2 treatment well, with only minor skin reactions at the injection site.

“Although follow-up studies will be necessary to investigate long-range benefits and test IL-2 in additional patients, the initial results are encouraging,” said Orange. “If cytokines can provide clinical benefits with low toxicity, this may represent an important advance and opportunity for all patients with Wiskott-Aldrich syndrome.”

Dr. Orange recognized for work in biology of NK cells

Orange has received international scientific recognition for his investigations of the biology of NK cells. In 1996, while a graduate student, he discovered that NK cells produce cytokines to participate in defending the body against viruses. Since that time, he has redefined the role of NK cell deficiencies in various human genetic disorders. At The Children’s Hospital of Philadelphia, Orange directs the Jeffrey Modell Diagnostic Center, which cares for children with primary immunodeficiency diseases.

Funding for the study

The National Institutes of Health, the National Center for Research Resources, the Jeffrey Modell Foundation, and the Children’s Hospital of Philadelphia Research Institute Foundation supported this study.

More information

Jordan S. Orange et al, “IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function,” The Journal of Clinical Investigation, April 201l. doi: 10.1172/JCI44862

Read the abstract.

Contact

John Ascenzi, Department of Public Relations, 267-426-6055, ascenzi@email.chop.edu

Published on in CHOP News